21st North Company Profile (OTCMKTS:ULGX)

About 21st North (OTCMKTS:ULGX)

21st North logo21st North Inc., formerly Urologix Inc., was engaged in developing, manufacturing, marketing and distributing medical products. The Company offered its products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The Company has no operations. The Company intends to dissolve.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:ULGX
  • CUSIP: N/A
  • Web: www.urologix.com
Average Prices:
  • 52 Week Range: $0.00 - $0.00
P/E:
  • Trailing P/E Ratio:
  • Foreward P/E Ratio: -0.01
  • P/E Growth:
Sales & Book Value:
  • Annual Revenue: $12 million
  • Price / Sales: 0.00
  • Book Value: ($0.38) per share
  • Price / Book: -0.01
Profitability:
  • EBIDTA: ($372,999.00)
Misc:
  • Average Volume: 36,586 shs.
  • Beta: 4.29
  • Short Ratio: 1.02
 

Frequently Asked Questions for 21st North (OTCMKTS:ULGX)

What is 21st North's stock symbol?

21st North trades on the OTCMKTS under the ticker symbol "ULGX."

How were 21st North's earnings last quarter?

21st North Inc (OTCMKTS:ULGX) posted its earnings results on Thursday, February, 5th. The company reported ($0.02) earnings per share for the quarter. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.80 million. View 21st North's Earnings History.

Who are some of 21st North's key competitors?

How do I buy 21st North stock?

Shares of 21st North can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of 21st North stock cost?

One share of 21st North stock can currently be purchased for approximately $0.00.

Analyst Ratings

Consensus Ratings for 21st North (OTCMKTS:ULGX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for 21st North (OTCMKTS:ULGX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for 21st North (OTCMKTS:ULGX)
Earnings by Quarter for 21st North (OTCMKTS:ULGX)
Earnings History by Quarter for 21st North (OTCMKTS:ULGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2015Q215($0.02)$3.80 million$3.10 millionViewListenView Earnings Details
8/19/2014Q4 14($0.17)$3.29 millionViewN/AView Earnings Details
2/4/2014Q4($0.05)$3.81 millionViewListenView Earnings Details
11/14/2012Q113($0.06)($0.05)$4.48 million$4.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for 21st North (OTCMKTS:ULGX)
Current Year EPS Consensus Estimate: $-0.210 EPS
Next Year EPS Consensus Estimate: $-0.230 EPS

Dividends

Dividend History for 21st North (OTCMKTS:ULGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for 21st North (OTCMKTS:ULGX)
Insider Ownership Percentage: 8.50%
Institutional Ownership Percentage: 0.09%
Insider Trades by Quarter for 21st North (OTCMKTS:ULGX)
Insider Trades by Quarter for 21st North (OTCMKTS:ULGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/26/2013Gregory FluetCEOBuy17,500$0.31$5,425.00View SEC Filing  
7/12/2013Mitchell DannDirectorBuy20,000$0.30$6,000.00View SEC Filing  
7/10/2013Gregory FluetCEOBuy25,000$0.24$6,000.00View SEC Filing  
7/9/2013Lisa A AckermannEVPBuy18,500$0.24$4,440.00View SEC Filing  
7/8/2013Gregory FluetCEOBuy66,400$0.19$12,616.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for 21st North (OTCMKTS:ULGX)
Latest Headlines for 21st North (OTCMKTS:ULGX)
Source:

Social

21st North (ULGX) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff